CLINUVEL Trial Results Show Drug Reduces DNA Damage
MELBOURNE, Australia, Jan. 16, 2023 (GLOBE NEWSWIRE) — Results from a clinical trial in a genetic DNA repair disorder show that a new drug – afamelanotide – may be able to reduce the development of skin cancers. The trial results are the first showing the potential of afamelanotide, a melanocortin drug under development by CLINUVEL, to protect and treat patients with xeroderma pigmentosum (XP), a rare disorder which causes extreme rates of skin cancers and forces patients to live in the dark.
Related news for (CLVLY)
- Afamelanotide in fair-skinned Parkinson’s patients
- Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
- Malibu shines a light on CLINUVEL’s pioneering work in photomedicine
- Global SCENESSE® demand drives increased CLINUVEL revenues, earnings
- CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals